Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first time.

The early data from UBT251 suggests it may be as similarly fast-acting as another of Novo Nordisk’s obesity hopefuls, the oral GLP-1 and amylin receptor amycretin, which showed 13.1% weight loss ...

The market for anti-obesity drugs has been growing for a while, but is finally about to take off with the entry of two global ...

A U.S. federal court has approved a settlement between Novo Nordisk (NVO) and Minnesota ending a longstanding litigation that accused three leading insulin manufacturers of charging excessive ...

Novo Nordisk joined the many pharmaceutical companies pushing back on government-negotiated drug pricing in the United States.

Novo Nordisk A/S, together with its subsidiaries ... The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes ...